Celcuity (CELC) Posts Fresh ESMO Data, Is The 60% Undervaluation Case Still Intact?

Celcuity (CELC) is back in focus after presenting fresh data at ESMO 2026 from its Phase 3 VIKTORIA-1 breast cancer trial and a Phase 1b/2 prostate cancer study of gedatolisib.

Celcuity’s share price has been volatile, with a 14.23% 7 day share price gain coming after a 30 day share price decline of 17.95% and a year to date share price fall of 35.11%. The 3 year total shareholder return remains very large at more than 7x, which may indicate that traders are now reassessing both growth prospects and risk after the latest ESMO 2026 data.

Capitalize on the renewed interest in Celcuity by scanning a curated set of oncology and biotech opportunities through 34 healthcare AI stocks that focus on similar data and catalyst driven stories.

After Celcuity’s sharp swing higher, investors are left weighing two instincts: lean into the momentum now, or wait to see if enthusiasm cools and the valuation resets.

Most Popular Narrative: 60% Undervalued

Celcuity’s most followed valuation narrative pegs fair value at about $161 per share, which sits well above the last close of $65.25 and puts the recent rally in a different light for anyone focused on long term potential rather than this week’s price action.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

See why 5 investors see Celcuity as 59% undervalued.

Result: Fair Value of $161.09 (UNDERVALUED)

Still, the bullish Celcuity narrative hinges on two pressure points: future regulatory decisions on gedatolisib and how physicians ultimately respond to competing PI3K targeted options.

Find out about the key risks to this Celcuity narrative.

Next Steps

Feeling torn between the upside story and the lingering concerns around Celcuity’s risk profile and pipeline timing is normal, so move quickly to review the detailed balance of 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Celcuity?

If Celcuity has sharpened your interest in catalyst driven stories, you can use this momentum to broaden your watchlist with fresh, data backed opportunities across the market.

• Target potential mispricings by running through the 28 high quality undervalued stocks screener, which filters for companies where fundamentals and market expectations appear out of sync.
• Strengthen your defense by scanning the 30 resilient stocks with low risk scores screener, which highlights resilient businesses with lower overall risk scores.
• Hunt for potential future standouts by checking the 21 high quality undiscovered gems screener, which surfaces quality companies still flying under most investors' radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com